Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a renowned technology company specializing in accelerated computing. This investment ...
In recent developments, Recursion Pharmaceuticals unveiled advances in its AI platform for drug discovery, forming collaborations with major pharmaceutical groups including Sanofi, Roche/Genentech, ...
Recursion Pharmaceuticals releases open-source 300-gigabyte dataset to improve AI use in biotech Salt Lake City-based biotech company Recursion Pharmaceuticals released a dataset of genetically ...
Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...
During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...
Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback